Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Clive S. Zent, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Betsy R. LaPlant, Thomas E. Witzig, Stephen M. Ansell, George J. Weiner

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint Dive into the research topics of 'Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates'. Together they form a unique fingerprint.

Medicine & Life Sciences